On Monday, November 25, 2024, the New York Post reported that a Missouri judge found that a state ban on transgender surgeries and hormone treatments for minors was constitutional. Judge Robert Craig Carter, of the 44th Judicial Circuit Court of Missouri, issued a 72-page ruling addressing challenges from LGBTQ civil rights advocates against the Save Adolescents From Experimentation Act, which was enacted last year.
In his ruling, Carter emphasized the unresolved medical ethics surrounding treatments for gender dysphoria in minors. He noted that the evidence presented during the trial indicated that the medical ethics concerning these treatments are not well established. He raised concerns about the potential for minors to obtain a range of medical treatments from professionals, warning that even harmful substances could be accessed if a single practitioner were willing to recommend them.
The Save Adolescents From Experimentation Act, signed into law by Missouri Governor Mike Parson in 2023, prohibits puberty blockers and hormone therapy for minors unless they are already undergoing such treatments. The law imposes penalties on medical professionals who violate its provisions, including the possibility of revocation of medical licenses and civil lawsuits with damages of at least $500,000 for successful claims.
Carter referenced a 2007 U.S. Supreme Court ruling that stated that state legislature options must be “epically broad” in cases involving significant medical and scientific uncertainties. This framing appears to support the state’s authority to regulate medical interventions for minors in this contentious area.
In response to the ruling, Lambda Legal and the ACLU of Missouri expressed strong disappointment and announced plans to appeal the decision. In a joint statement, the organizations criticized the ruling for signaling an alarming acceptance of discrimination and for disregarding extensive trial evidence and the testimonies of transgender individuals and healthcare providers in Missouri. They asserted that the ruling denies transgender minors and Medicaid beneficiaries access to necessary, evidence-based medical care.
The organizations pointed out the substantial testimony provided during the trial, including accounts from parents of transgender youth, transgender adults who have benefited from such care, and dedicated healthcare providers. They argued that the state has prioritized political considerations over the health and well-being of its citizens, stating, “This ruling sends a chilling message that, for some, compassion and equal access to health care are still out of reach.”
As it stands, Missouri is the first state where a trial court has upheld such a ban, amidst a landscape where at least 26 states have enacted similar policies. Conversely, 24 states and Washington, D.C. maintain laws that protect access to transgender medical interventions.
Critics argue that minors lack the maturity to make informed decisions regarding interventions that could significantly alter their physical development. Data from Komodo Health Inc. indicated that in 2021, there were 4,231 hormone therapy procedures performed on minors aged 6 to 17, alongside 1,390 puberty blocker treatments and 282 mastectomies conducted on girls aged 13 to 17. Furthermore, diagnosed cases of gender dysphoria among minors surged from 15,172 in 2017 to 42,167 in 2021, according to the same dataset.
Source: New York Post
